The Indian Pharmaceutical Alliance (IPA) has announced the appointment of Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, as its new President. Dr. Patel will lead the industry body for the next two years, succeeding Samina Hamied, Executive Vice Chairperson of Cipla Ltd., who successfully steered the Alliance through its last term.

Dr. Sharvil Patel, a seasoned leader in the pharmaceutical sector, brings with him extensive experience in shaping the growth trajectory of Zydus Lifesciences, one of India’s leading pharmaceutical and healthcare companies. Under his leadership, Zydus has expanded its global footprint, strengthened research and development initiatives, and contributed significantly to innovation in affordable healthcare solutions.

The IPA, which represents 25 leading research-based Indian pharmaceutical companies, plays a pivotal role in advancing India’s position as the “Pharmacy of the World.” The Alliance works closely with stakeholders to ensure patient safety, promote quality standards, encourage innovation, and drive access to affordable medicines globally.

Expressing his vision as the new President, Dr. Sharvil Patel said, “It is an honor to take on this responsibility at such a crucial time for the pharmaceutical industry. India has an opportunity to further strengthen its global leadership in generics, biologics, and innovation-led healthcare. As President of the IPA, I look forward to working with industry peers, regulators, and policymakers to ensure that we collectively contribute towards better healthcare outcomes and reinforce India’s position in global healthcare.”

Outgoing President Samina Hamied congratulated Dr. Patel on his appointment and highlighted the IPA’s continued focus on patient-centric innovation and collaboration. “The last two years have been transformative for the industry, and I am confident that under Dr. Patel’s leadership, the IPA will continue to build resilience, foster innovation, and uphold the highest standards of quality and trust.”

With this leadership transition, the IPA reaffirms its commitment to promoting India’s pharmaceutical excellence and driving sustainable growth while ensuring equitable access to medicines both in India and globally.